Neonax (AIO-PAK-0313): Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: A phase II study of the AIO Pancreatic Cancer Group

被引：0
|
作者：
Ettrich, Thomas Jens
Berger, Andreas W.
Muche, Rainer
Lutz, Manfred P.
Prasnikar, Nicole
Uhl, Waldemar
Tannapfel, Andrea
Heinemann, Volker
Seufferlein, Thomas
机构：
[1] Univ Ulm, Dept Internal Med 1, D-89069 Ulm, Germany
[2] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany
[3] Caritasklinikum, Saarbrucken, Germany
[4] Klinikum Ludwigsburg, Ludwigsburg, Germany
[5] Ruhr Univ Bochum, Dept Surg, Bochum, Germany
[6] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany
[7] Univ Munich, Klinikum Grosshadern, Dept Med Oncol, D-80539 Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 03期
关键词：
D O I：
10.1200/jco.2015.33.3_suppl.tps497
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS497
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Miyasaka, Yoshihiro
    Nakamura, Masafumi
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (Suppl 3) : S739 - S740
  • [42] Maintenance treatment with gemcitabine after gemcitabine plus Nab-paclitaxel in advanced pancreatic cancer
    Kodama, Tomoko
    Nakazawa, Junichi
    Kawahira, Masahiro
    Ymasuji, Akihiro
    Iwashita, Yuji
    Hori, Takeshi
    Kawahira, Machiko
    Arima, Shiho
    Tubouchi, Hirohito
    Ido, Akio
    ANNALS OF ONCOLOGY, 2022, 33 : S484 - S484
  • [43] ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
    Yoshihiro Miyasaka
    Masafumi Nakamura
    Annals of Surgical Oncology, 2019, 26 : 739 - 740
  • [44] ASO Visual Abstract: A Prospective, Multicenter, Phase II, Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement
    Naoki Ikenaga
    Yoshihiro Miyasaka
    Takao Ohtsuka
    Kohei Nakata
    Tomohiko Adachi
    Susumu Eguchi
    Kazuyoshi Nishihara
    Masafumi Inomata
    Hiroshi Kurahara
    Toru Hisaka
    Hideo Baba
    Hiroaki Nagano
    Toshiharu Ueki
    Hirokazu Noshiro
    Shoji Tokunaga
    Kousei Ishigami
    Masafumi Nakamura
    Annals of Surgical Oncology, 2023, 30 : 205 - 206
  • [45] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [46] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [47] Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC)
    Olowokure, Olugbenga
    Torregroza-Sanchez, Maria Patricia
    Bedoya-Apraez, Ivan Dario
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2013, 4 (02) : E16 - E18
  • [48] Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
    Jameson, Gayle S.
    Hosein, Peter J.
    Pierce, Erin
    Kamgar, Mandana
    Gordon, Michael S.
    Snyder, Courtney
    Roe, Denise J.
    Wertheim, Betsy C.
    Davey, Marina
    Barrett, Michael T.
    Von Hoff, Daniel D.
    Borazanci, Erkut
    CANCER MEDICINE, 2024, 13 (12):
  • [49] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
  • [50] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
12345